Colorectal Cancer in Young Adults: Study of Incidence, Survival, and Prognostic Factors in Tarragona, Spain
NCT ID: NCT07026955
Last Updated: 2025-06-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
59 participants
OBSERVATIONAL
2024-10-01
2025-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Life and Care of Patients With Colorectal Cancer Before Age 65 and Their Kindred
NCT04451343
Early Diagnosis of Colorectal Cancer Based on a Non-invasive Metabolomics Profile
NCT06452745
Observational Cross-reactivity Study for Colorectal Cancer Diagnosis
NCT06889844
The Life and Care of Colorectal Cancer Patients After 65 Years and Their Family
NCT04458740
Incidence and Risk Factors of Early Onset Colorectal Cancer
NCT05184751
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This descriptive, longitudinal, observational, retrospective study included patients under 50 diagnosed with colorectal cancer at HJ23 between 2019 and 2024. The protocol was approved by the CEIm IISPV (ref. 009/2024)
Study Population
Participants Data were obtained from patients under 50 years of age diagnosed with CRC and evaluated by the colorectal cancer multidisciplinary team (MDT) at the HJ23 during the period 2019-2024.
Inclusion criteria included all patients under 50 years of age diagnosed with CRC and evaluated by the MDT during the specified period.
Exclusion criteria comprised patients over 50 years of age, those with primary tumors of non-colorectal origin, and individuals diagnosed with polyps with low-grade dysplasia, hyperplastic polyps, or other non-neoplastic colorectal conditions.
Study Methods
Data were obtained from the registry of patients presented at the Multidisciplinary Colorectal Cancer Committee of the HJ23 between 2019 and 2024.
The hospital informatic team provided a refined list of medical record numbers for patients under 50 years of age evaluated by the committee.
The information was encoded into a password-protected Microsoft Access database hosted on the hospital intranet. Subsequently, detailed review of medical records was conducted, resulting in a pseudonymized dataset for analysis.
Study Variables Sociodemographic variables included sex (male or female), age (under 50), and referring hospital to assess the demographic distribution by origin.
Clinical characteristics included date of first symptom, reason for consultation, poor prognostic factors, and tumor staging using the TNM classification , based on clinical, imaging, and/or pathological data.
Management and follow-up variables included date of presentation to the MDT, the treatment decision taken, presence of local recurrence or metastases, date of last surgical follow-up, and, if applicable, date of death.
Diagnostic procedures included colonoscopy, date, distance from anal verge in centimeters, and histopathological findings. Imaging studies included the performance of CT scans, recording whether performed and the date of examination.
Surgical treatment variables included whether surgery was performed, date of surgery, surgical approach (open, laparoscopic, robotic).
Histopathological variables for operated patients included the pathological evaluation of the surgical specimen, TNM staging, lymphovascular invasion, distant metastases, tumor budding grade (low, intermediate, high, or not assessable), and MSH2/MSH6 mismatch repair protein expression (preserved/not preserved). Postoperative complications were classified using the Clavien-Dindo scale. Data on genetic counseling were also recorded, including conclusions on pathogenic variants, variants of uncertain significance, or benign findings.
Statistical Analysis Quantitative variables with a normal distribution were expressed as mean and standard deviation (SD); otherwise, they were presented as median and interquartile range (IQR). Categorical variables were described using mode and proportions. The Shapiro-Wilk test was used to assess the normality of continuous variables. A p-value \< 0.05 was considered statistically significant. If normality was not confirmed, p-values were obtained using permutation tests.
Group comparisons were made using Fisher's exact test for categorical variables, and the Student's t-test or ANOVA for normally distributed quantitative variables. For non-normal distributions, the Wilcoxon-Mann-Whitney test was used for two groups, and the Kruskal-Wallis test for more than two groups. Fisher's and McNemar's tests were used for contingency tables, as appropriate.
All analyses were performed using STATA© (StataCorp), conducted by a statistician specialized in data processing and analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
colorectal cancer in patients under 50 years of age
colorectal cancer in patients over 50 years of age
description
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
colorectal cancer in patients over 50 years of age
description
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diagnosed: colorectal cancer
Exclusion Criteria
* Primary tumors of non-colorectal origin
* individuals diagnosed with polyps with low-grade dysplasia, hyperplastic polyps
* other non-neoplastic colorectal conditions.
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Joan XXIII University Hospital
OTHER
HJ23
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jordi Elvira Lopez
Principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Universitario de Tarragona Joan XXIII
Tarragona, Tarragona, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
009/2024
Identifier Type: OTHER
Identifier Source: secondary_id
CGD-HJ23
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.